Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

70.34
BATS BZX Real-Time Price
As of 2:40pm ET
 -0.31 / -0.44%
Today’s Change
66.93
Today|||52-Week Range
83.58
-3.43%
Year-to-Date
Manning & Napier Advisors, Inc Buys Bristol-Myers Squibb Company, Regeneron Pharmaceu...
12:44pm / GuruFocus News - Paid Partner Content
Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next
Jan 13 / MotleyFool.com - Paid Partner Content
Better Buy: Exelixis, Inc. vs. Novartis
11:49am / MotleyFool.com - Paid Partner Content
4 Signs Glaxo's Turnaround Is Taking Hold
Jan 13 / MotleyFool.com - Paid Partner Content
John G Ullman & Associates Inc Buys Novartis AG, Baxter International Inc, CalAmp Cor...
Jan 20 / GuruFocus News - Paid Partner Content
ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
Jan 13 / Zacks.com - Paid Partner Content
Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
Jan 20 / Zacks.com - Paid Partner Content
Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
Jan 13 / Zacks.com - Paid Partner Content
Are You Undervaluing These 3 Biopharmas' Pipelines?
Jan 20 / MotleyFool.com - Paid Partner Content
3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference
Jan 11 / MotleyFool.com - Paid Partner Content
Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug
Jan 18 / TheStreet.com - Paid Partner Content
Why Novartis Dropped 15.1% in 2016
Jan 11 / MotleyFool.com - Paid Partner Content
Watch Point Trust Co Buys Comcast Corp, Newell Brands Inc, Novartis AG, Sells Abbott ...
Jan 18 / GuruFocus News - Paid Partner Content
The 1 Biotech Stock I Want to Own in 2017
Jan 11 / MotleyFool.com - Paid Partner Content
Why Bristol-Myers Squibb May Be a Merger Target Soon
Jan 17 / TheStreet.com - Paid Partner Content
Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
Jan 09 / Zacks.com - Paid Partner Content
Novartis to Conduct Trial on Obese, Type II Diabetes Patients
Jan 13 / Zacks.com - Paid Partner Content
Teva Falls on Disappointing 2017 Sales & Earnings Guidance
Jan 09 / Zacks.com - Paid Partner Content